Compare CVGI & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVGI | CRBU |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 166.6M |
| IPO Year | 2004 | 2021 |
| Metric | CVGI | CRBU |
|---|---|---|
| Price | $4.57 | $1.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 359.4K | ★ 1.9M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.18 | 3.64 |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $755,231,000.00 | N/A |
| Revenue This Year | $4.84 | $1.63 |
| Revenue Next Year | $5.36 | $10.93 |
| P/E Ratio | $115.50 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $1.29 | $1.38 |
| 52 Week High | $5.88 | $3.53 |
| Indicator | CVGI | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 37.59 |
| Support Level | $4.32 | $1.39 |
| Resistance Level | $5.77 | $1.73 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.67 | 5.56 |
Commercial Vehicle Group Inc and its subsidiaries are a globalised provider of systems, assemblies, and components to international commercial vehicle markets and electric vehicle markets. It delivers real solutions to complex design, engineering, and manufacturing problems while creating positive change for customers, industries, and communities it serves. The company has its manufacturing operations in the United States, Mexico, China, the United Kingdom, the Czech Republic, Ukraine, Morocco, Thailand, India, and Australia. Organisations' products are mainly sold in North America, Europe, and the Asia-Pacific region. It has three segments: Global Seating Segment, Global Electrical systmem, and Trim Systems and Components Segment, with the majority of revenue from Global Seating Segment.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.